(RTTNews) - atai Life Sciences (ATAI) announced Friday that Perception Neuroscience's Phase 2a clinical trial of PCN -101 or R-ketamine failed to its primary endpoint of a statistically significant ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback